Riliprubart vs Placebo for Refractory CIDP (MOBILIZE Trial)
(MOBILIZE Trial)
Trial Summary
What is the purpose of this trial?
This study tests whether riliprubart can help adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) whose disease has not responded to standard treatments like IVIg, SCIg, or corticosteroids. Participants are randomly assigned to receive either riliprubart or placebo for 24 weeks, after which all participants can continue into an open-label extension where everyone receives riliprubart.
Why do researchers think this study treatment might be promising?
Riliprubart targets inflammation pathways differently than traditional CIDP therapies by blocking C1s, a part of the immune system that can harm nerves in CIDP. By acting on this specific immune pathway, the study drug may offer more targeted relief for people whose CIDP has not responded to current standards of care.
Timeline
Screening
Participants are evaluated to confirm eligibility
Treatment
Participants receive regular doses of either riliprubart or placebo.
Open-label Extension
All participants receive open-label riliprubart through Week 48.
Follow-up
Participants are monitored after completing treatment through two clinic visits and some phone calls.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sanofi
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.